Yahoo Finance

Estimated Discount To Fair Value: 46.4%

Shanghai INT Medical Instruments is trading at HK$28.95, significantly below its estimated fair value of HK$54.03, suggesting it may be undervalued based on cash flows. Revenue is projected to grow 28.7% annually, outpacing the Hong Kong market's 7.8%, while earnings are expected to rise by 27.2% per year over the next three years—well above the market average of 11.4%. However, shareholder dilution occurred last year and future return on equity is forecasted to remain low at 14.7%.

• Insights from our recent growth report point to a promising forecast for Shanghai INT Medical Instruments' business outlook.

• Navigate through the intricacies of Shanghai INT Medical Instruments with our comprehensive financial health report here.

IMMOFINANZ

Overview: IMMOFINANZ AG is a real estate company that acquires, develops, owns, rents, and manages properties primarily in Austria, Germany, Poland, the Czech Republic, Hungary, Romania, Slovakia and the Adriatic region with a market cap of €2.08 billion.

Operations: The company's revenue is primarily derived from its retail segment, which generates €298.13 million, and its office segment, contributing €237.95 million.

Estimated Discount To Fair Value: 27.9%

IMMOFINANZ is trading at €15.1, significantly below its estimated fair value of €20.95, indicating it might be undervalued based on cash flows. Despite a volatile share price recently and low forecasted return on equity (7.6%) in three years, the company is expected to become profitable within that timeframe with earnings growth projected at 70.61% annually. Recent earnings showed improved revenue but a sharp decline in quarterly net income compared to last year.

• Our earnings growth report unveils the potential for significant increases in IMMOFINANZ's future results.

• Take a closer look at IMMOFINANZ's balance sheet health here in our report.

Taking Advantage

• Discover the full array of 910 Undervalued Stocks Based On Cash Flows right here.

• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.

• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include OM:XVIVO SEHK:1501 and WBAG:IIA.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com